Bitter-Zoet 2: The Effect of Long-term Momordica Charantia Supplementation on Blood Glucose Levels
Study Details
Study Description
Brief Summary
The study is a parallel, double blind, controlled trial in which study participants will receive a 12-week intervention with 3.6 g/d dried bitter-gourd supplements or a reference intervention with 3.6 g/d dried cucumber supplements. Research subjects will come to the research facility for a test day on four occasions, with an interval of 4 weeks. The main study parameter is fasting levels of plasma glucose.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Bitter gourd (BG) (Momordica charantia) is a highly nutritive vegetable from the cucumber family. The objective is to assess the impact of 12-weeks of BG supplementation on blood glucose levels in subjects with impaired fasting glucose levels. In a previous trial (Bitter-Zoet NL70259.081.19) the short-term effects of BG (4 weeks) were studied, but no effect was observed. In the current trial a different BG cultivar is chosen, the intervention period is prolonged, the dosage per day is higher and study subjects with slightly higher fasting blood glucose levels will be included. The study is a parallel, double blind, controlled trial in which study participants will receive a 12-week intervention with 3.6 g/d dried bitter-gourd supplements or a reference intervention with 3.6 g/d dried cucumber supplements. Research subjects will come to the research facility for a test day on four occasions, with an interval of 4 weeks. The main study parameter is fasting levels of plasma glucose. Secondary outcome measures are glucose tolerance, HbA1c, insulin and HOMA-IR and HOMA-B levels.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Bitter-gourd dried bitter-gourd supplements |
Other: Bitter-gourd
12-week intervention of 3.6 grams of dried bitter-gourd supplements
|
| Active Comparator: Cucumber dried cucumber supplements |
Other: Cucumber
12-week intervention of 3.6 grams of cucumber supplements
|
Outcome Measures
Primary Outcome Measures
- change in fasting plasma glucose concentrations [Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)]
marker for glucose metabolism
Secondary Outcome Measures
- change in 2hour plasma glucose concentrations after a 75-gram OGTT [Baseline (before supplementation (T0)) and after 12 weeks (T4)]
marker for glucose metabolism
- change in HbA1c [Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)]
marker for glucose metabolism
- change in insulin [Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)]
marker for glucose metabolism
- change in HOMA-IR levels [Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)]
marker for glucose metabolism
- change in HOMA-B levels [Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)]
marker for glucose metabolism
Other Outcome Measures
- change in ALAT [Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)]
liver enzyme (study safety parameter)
- change in ASAT [Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)]
liver enzyme (study safety parameter)
- change in eGFR [Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)]
estimated glomerular filtration rate (study safety parameter)
- change in creatinine [Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)]
kidney function (study safety parameter)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
age 40-75yrs
-
BMI >25 kg/m2
-
Having a fasting glucose >6.1 mmol/L
Exclusion Criteria:
-
Use of medication/supplements that may influence the study results, such as metformin, gliclazide, glimepiride, tolbutamide, insulin, sitagliptin (DPP4 inhibitor), liraglutide (GLP-1 agonist), acarbose, repaglinide, pioglitazone, corticosteroids (systemically) , SGLT-2 inhibitors, (judged by our research physician)
-
Having a fasting glucose >11.0 mmol/L
-
History of gastro-intestinal surgery or having (serious) gastro-intestinal complaints
-
History of liver dysfunction (cirrhosis, hepatitis) or liver surgery
-
Reported slimming, medically prescribed or other extreme diets
-
Reported weight loss or weight gain of > 5 kg in the month prior to pre-study screening
-
Not willing to give up blood donation during the study
-
Current smokers
-
Alcohol intake ≥14 glasses (women) or >21 glasses (men) of alcoholic beverages per week, on average
-
pregnant or lactating (self-reported)
-
Abuse of illicit drugs (soft- and hard drugs)
-
Food allergies for products that we use in the study
-
Participation in another clinical trial at the same time
-
Being an employee of the Food, Health & Consumer Research group of Wageningen Food & Biobased Research or dept. human nutrition and health of Wageningen University.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Stichting Wageningen Research | Wageningen | Gelderland | Netherlands | 6708 WG |
Sponsors and Collaborators
- Wageningen University and Research
Investigators
- Principal Investigator: Sandra van der Haar, MSc, Stichting Wageningen Research
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NL79294.091.21